Targeting AT
2
receptors in renal disease
Am J Physiol Renal Physiol
.
2021 Jun 1;320(6):F1025-F1027.
doi: 10.1152/ajprenal.00142.2021.
Epub 2021 May 3.
Author
Tianxin Yang
1
2
Affiliations
1
Internal Medicine, University of Utah, Salt Lake City, Utah.
2
Veterans Affairs Medical Center, Salt Lake City, Utah.
PMID:
33938241
PMCID:
PMC8285648
DOI:
10.1152/ajprenal.00142.2021
No abstract available
Publication types
Editorial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Comment
MeSH terms
Humans
Kidney Diseases*
Receptor, Angiotensin, Type 2
Substances
Receptor, Angiotensin, Type 2
Grants and funding
I01BX004871/U.S. Department of Veterans Affairs (VA)
R01 HL135851/HL/NHLBI NIH HHS/United States
ik6BX005223/U.S. Department of Veterans Affairs (VA)
R01 DK104072/DK/NIDDK NIH HHS/United States
HL135851/HHS | National Institutes of Health (NIH)
DK104072/HHS | National Institutes of Health (NIH)
I01 BX004871/BX/BLRD VA/United States
HL139689/HHS | National Institutes of Health (NIH)
R01 HL139689/HL/NHLBI NIH HHS/United States